Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
91 hedge funds and large institutions have $88.4M invested in Enzo Biochem, Inc. in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 36 reducing their positions, and 17 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
10% less funds holding
Funds holding: 101 → 91 (-10)
32% less capital invested
Capital invested by funds: $130M → $88.4M (-$41.4M)
39% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 36
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$3.16M |
| 2 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$1.11M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.01M |
| 4 |
Renaissance Technologies
New York
|
+$409K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$221K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.48M |
| 2 |
AG
Algert Global
San Francisco,
California
|
-$927K |
| 3 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$861K |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$775K |
| 5 |
DC
Davenport & Co
Richmond,
Virginia
|
-$652K |
ENZ Hedge Fund Activity: Q4 2018 in Review
91 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2018, worth a combined $88.4M — down 32% from $130M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ENZ and 7 opened new positions — a net loss of 10 holders — while 36 trimmed existing stakes and 22 added.
The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $3.16M. The largest seller was Vanguard Group, cutting an estimated $4.48M.
- 91 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2018, down from 101 in Q3 2018.
- Funds reported $88.4M of Enzo Biochem, Inc. stock for Q4 2018, down 32% quarter-over-quarter.
- 7 funds opened new Enzo Biochem, Inc. positions in Q4 2018 and 17 closed out, a net change of -10 holders.
- The largest Enzo Biochem, Inc. buyer in Q4 2018 was Manulife (Manufacturers Life Insurance), an estimated $3.16M added.
- The largest Enzo Biochem, Inc. seller in Q4 2018 was Vanguard Group, an estimated $4.48M sold.
Based on aggregated 13F filings for Q4 2018.